Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of “Hold” from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has received an average recommendation of “Hold” from the twenty-eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and nine have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $33.84.

A number of equities analysts recently weighed in on SRPT shares. Bank of America lifted their target price on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an “underperform” rating in a research note on Wednesday, October 22nd. Wedbush lifted their price objective on Sarepta Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Mizuho raised Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $19.00 to $26.00 in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sarepta Therapeutics in a research note on Monday, December 29th. Finally, Guggenheim lowered their target price on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a report on Wednesday, November 5th.

Insiders Place Their Bets

In other news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the sale, the chief operating officer owned 193,300 shares in the company, valued at $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 7.60% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SRPT. iSAM Funds UK Ltd purchased a new stake in shares of Sarepta Therapeutics in the third quarter worth approximately $25,000. Ancora Advisors LLC grew its holdings in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,000 shares in the last quarter. Byrne Asset Management LLC bought a new stake in Sarepta Therapeutics during the third quarter worth $33,000. Allworth Financial LP raised its position in Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,721 shares during the last quarter. Finally, Parallel Advisors LLC lifted its stake in Sarepta Therapeutics by 165.3% during the 3rd quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 1,256 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $19.73 on Thursday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 2.95. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $120.05. The company has a 50 day simple moving average of $21.59 and a two-hundred day simple moving average of $19.94. The company has a market capitalization of $2.07 billion, a PE ratio of -6.55, a P/E/G ratio of 0.51 and a beta of 0.39.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The firm had revenue of $399.36 million during the quarter, compared to analyst estimates of $331.51 million. During the same quarter last year, the firm posted $0.62 EPS. The firm’s revenue for the quarter was down 14.5% on a year-over-year basis. Research analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.